

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 May 2021 (20.05.2021)(10) International Publication Number
WO 2021/094832 A8

(51) International Patent Classification:

C07D 207/263 (2006.01) A61P 25/28 (2006.01)
 C07D 401/06 (2006.01) A61P 25/06 (2006.01)
 C07D 403/06 (2006.01) A61K 31/4015 (2006.01)
 C07D 413/06 (2006.01)

(21) International Application Number:

PCT/IB2020/000962

(22) International Filing Date:

12 November 2020 (12.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2019-206311 14 November 2019 (14.11.2019) JP

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **IKEDA, Shuhei**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **KAMATA, Makoto**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **OGURO, Yuya**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **AIDA, Jumpei**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **TAWARAISHI, Taisuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **WAKABAYASHI, Takeshi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **OYABU, Norio**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **OCHIDA, Atsuko**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **IWANAGA, Kouichi**; c/o Takeda

Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **YAMAMOTO, Satoshi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **MURAKAMI, Masataka**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **NAKAMURA, Minoru**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **YAMAGUCHI, Fumie**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP). **YUKAWA, Takafumi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi 2-chome, Fujisawa-shi, Kanagawa, 251-0012 (JP).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC NMDA ANTAGONISTS



(57) Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

(48) Date of publication of this corrected version:

02 June 2022 (02.06.2022)

(15) Information about Correction:

see Notice of 02 June 2022 (02.06.2022)